Please select the eligibility criteria that correspond to the clinical trial below.
Title: Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Brief Summary: A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.


Options:
A: Inclusion Criteria:

* Males
* 60 years or over
* Unilateral ischemic stroke involving subcortical white matter or Basal Ganglia 6 months to 5 years before entry
* NIHSS score minimum 6 with hemiparesis (2 or more for motor arm and leg)
* Neurologically stable for 2 m
* modified Rankin score of 2-4
* Fit for general anesthesia, neurosurgery
* Capacity to consent
* Infarct at least 1cm diameter

Exclusion Criteria:

* Structural brain vascular lesions requiring surgery or increasing the risk of stereotaxic implantation
* Unstable medical conditions with expected survival \<12 months
* Any medical condition that would impair participation (eg progressive neurological disorders, mental illness)
* Major surgery within 30 days
* Previous allogeneic tissue transplant
* MMSE \< 24
* Epilepsy
* Coagulation disorders or anticoagulant treatment that cannot be interrupted
* Stimulants, botox, tamoxifen
* Contraindications to MRI
B: Inclusion Criteria:

* Documented history of one completed ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement
* Between 6 and 60 months post-stroke, and having a motor neurological deficit
* No significant further improvement with physical therapy/rehabilitation
* Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) scans of the head

Exclusion Criteria:

* History of more than 1 symptomatic stroke
* History of seizures
* History or presence of any other major neurological disease
* Myocardial infarction within prior 6 mos.
* Known presence of any malignancy except squamous or basal cell carcinoma of the skin
* Participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of study entry
* Contraindications to head CT, MRI, or PET
* Pregnant or lactating
C: Inclusion Criteria:

* Symptoms and signs of clinically definite middle cerebral artery acute stroke.
* Time of stroke onset is known and treatment can be started between day 5 and 9 of onset.
* DWI-MRI has reliably shown relevant acute ischemic lesions
* Extracranial duplex/transcranial Doppler must confirm intra/extracranial arteries permeability.
* The stroke is severe (NIH Stroke Scale \>= 8 before procedure).
* An age range of 18-80 years old.

Exclusion Criteria:

* Patients out of inclusion age range.
* Lacunar infarction.
* Patients with cancer.
* Patients with present or previous malignant disease during the last 5 years, except for basal cell carcinoma.
* Hematological causes of stroke.
* Severe co-morbidity.
* Hepatic or renal dysfunction.
* The patient is female and of childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding.
* Patient is likely to be unavailable for follow-up.
* Patient with evidence of life threatening infection of life threatening illness.
* Patient was already dependent in activities of daily living before the present acute stroke.
D: Inclusion Criteria:

* Male or female subjects between 18 and 83 years of age (inclusive)
* Clinical diagnosis of cortical cerebral ischemic stroke
* Occurrence of a moderate to moderately severe stroke

Exclusion Criteria:

* Presence of a lacunar or a brainstem infarct
* Reduced level of consciousness
* Major neurological event such as stroke or clinically significant head trauma within 6 months of study

Answer: D